A meta-analysis of 145,000+ patients shows GLP-1 drugs cut cardiovascular events by 14%, with blood pressure reduction and weight loss both independently contributing — and better BP monitoring reveals a stronger cardiac benefit than office readings suggest.
14% MACE reductionGLP-1 receptor agonists reduced major adverse cardiovascular events by 14% across 145,322 patients, with blood pressure reduction showing a stronger signal when measured by ambulatory monitoring
What the researchers found
A meta-analysis of 21 randomized trials with 145,322 participants found that GLP-1 receptor agonists reduced major adverse cardiovascular events (MACE) by 14% (HR=0.86, 95% CI: 0.81–0.91). Both blood pressure reduction and weight loss independently contributed to this cardiovascular benefit.
The key insight: when blood pressure was measured using ambulatory monitoring (a 24-hour wearable device) rather than single office readings, the association between BP reduction and cardiovascular benefit was much stronger. This suggests that GLP-1 drugs' blood pressure effects may be underestimated by standard office BP measurements, and that BP lowering is a more important driver of their cardiovascular protection than previously appreciated.
Why it matters
There's been a debate about whether GLP-1 drugs protect the heart mainly through weight loss or through blood pressure reduction. This meta-analysis shows both matter independently, but that BP reduction may be a bigger contributor than we thought — we just weren't measuring it accurately enough. This supports using GLP-1 drugs specifically for hypertensive patients, including those with difficult-to-treat resistant hypertension.
The numbers in context
21 RCTs · n=145,322 · HR=0.86 for MACE · 95% CI: 0.81–0.91 · SBP and weight independently associated with MACE reduction · Stronger BP signal with ambulatory monitoring
How the study worked
Systematic review and meta-analysis of randomized controlled trials from January 2015 to April 2025 evaluating GLP-1RA or dual GLP-1/GIP agonists. Eligible trials reported MACE outcomes and changes in systolic blood pressure and/or weight. Random-effects meta-analyses pooled hazard ratios. Meta-regressions assessed whether BP and weight reductions mediated MACE reduction. Subgroup analyses compared trials using clinical BP versus ambulatory BP monitoring.
Who was studied
145,322 participants across 21 randomized controlled trials, including patients with type 2 diabetes and/or obesity
What this study cannot tell us
Meta-regression can identify associations but cannot prove causation — the analysis cannot definitively determine what proportion of cardiovascular benefit comes from BP reduction versus weight loss versus other mechanisms. The subgroup analysis by BP measurement method depends on how individual trials measured BP, which varied. Individual patient data were not available, limiting the ability to control for all confounders.
How to read the evidence
This is a meta-analysis of 21 randomized controlled trials with over 145,000 participants — one of the highest levels of evidence. The meta-regression approach provides strong associative evidence, though it cannot definitively establish causation for the mediation effects.
When this study was published
Published in 2026 with literature through April 2025. This is among the most current and comprehensive meta-analyses of GLP-1 drug cardiovascular effects.
The bigger picture
This meta-analysis shifts the narrative about how GLP-1 drugs protect the heart. Rather than being primarily 'weight loss drugs that happen to help the heart,' the data suggests BP reduction is a co-equal or even stronger contributor. This has clinical implications: it supports prescribing GLP-1 drugs specifically for patients with hypertension — including resistant hypertension that doesn't respond well to standard BP medications. It also highlights the value of ambulatory BP monitoring over office readings for assessing GLP-1 drug benefits.
Questions still open
- Should ambulatory blood pressure monitoring become standard for evaluating GLP-1 drug efficacy in hypertensive patients?
- Does the dual GLP-1/GIP agonist tirzepatide show a stronger blood pressure effect than single GLP-1 agonists like semaglutide?
- What proportion of GLP-1 drugs' cardiovascular benefit comes from mechanisms beyond BP and weight — such as anti-inflammatory or anti-atherosclerotic effects?
Common questions
Do GLP-1 drugs protect the heart mainly through weight loss or blood pressure reduction?
Should people with high blood pressure consider GLP-1 drugs?
Read the original research
Ambulatory blood pressure monitoring strengthens the cardiovascular signal of GLP-1RA: a meta-analysis of blood pressure and weight mediation.
Journal of hypertension, 44(1), 123-129
Citation
Renna, Nicolás F; Ramirez, Eliel Ivan; Arrupe, Matias Fernando; Ramirez, Jesica Magalí. (2026). Ambulatory blood pressure monitoring strengthens the cardiovascular signal of GLP-1RA: a meta-analysis of blood pressure and weight mediation.. Journal of hypertension, 44(1), 123-129. https://doi.org/10.1097/HJH.0000000000004158